[SaneVax: Norway’s Vaccibody is in the process of developing a therapeutic vaccine for treatment of CIN 1 or 2 lesions associated with HPV 16. They anticipate being ready for clinic by 2013.  The question is, why are they even developing a vaccine to treat lesions that normally clear on their own? When is the pharmaceutical industry […]